These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11991244)

  • 1. Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients.
    Borawski J; Myśliwiec M
    Clin Appl Thromb Hemost; 2002 Jan; 8(1):77-84. PubMed ID: 11991244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients.
    Borawski J; Pawlak K; Myśliwiec M
    Nephron; 2002 Aug; 91(4):671-81. PubMed ID: 12138272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients.
    Borawski J; Myśliwiec M
    Nephrol Dial Transplant; 2002 Apr; 17(4):637-44. PubMed ID: 11917058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
    Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
    Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of recombinant human erythropoietin on functional and injury endothelial markers in peritoneal dialysis patients.
    Aguilera A; Selgas R; Ruiz-Caravaca ML; Bajo MA; Cuesta MV; Plaza MA; Hernanz A
    Perit Dial Int; 1999; 19 Suppl 2():S161-6. PubMed ID: 10406511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells.
    Nagai T; Akizawa T; Kohjiro S; Koiwa F; Nabeshima K; Niikura K; Kino K; Kanamori N; Kinugasa E; Ideura T
    Kidney Int; 1996 Jul; 50(1):102-7. PubMed ID: 8807578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy.
    Borawski J; Naumnik B; Mysliwiec M
    Clin Appl Thromb Hemost; 2002 Oct; 8(4):359-67. PubMed ID: 12516686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response.
    Borawski J; Naumnik B; Pawlak K; Mysliwiec M
    Nephrol Dial Transplant; 2001 Jul; 16(7):1442-7. PubMed ID: 11427638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy.
    Malyszko J; Malyszko JS; Borawski J; Rydzewski A; Kalinowski M; Azzadin A; Mysliwiec M; Buczko W
    Thromb Res; 1995 Jan; 77(2):133-43. PubMed ID: 7740505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients.
    Kuriyama S; Hopp L; Yoshida H; Hikita M; Tomonari H; Hashimoto T; Sakai O
    Am J Hypertens; 1996 May; 9(5):426-31. PubMed ID: 8735172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the 6-month anemia therapy with erythropoietin on renal function and some hemodynamic parameters in predialysis patients.
    Tomczak-Watras W; Strózecki P; Zuchora Z; Szefer J; Manitius J
    Pol Arch Med Wewn; 2009; 119(1-2):45-51. PubMed ID: 19341178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis.
    Lip GY; Blann AD; Jones AF; Beevers DG
    Am Heart J; 1997 Oct; 134(4):764-71. PubMed ID: 9351746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin.
    Małyszko JS; Małyszko J; Pawlak K; Pawlak D; Buczko W; Myśliwiec M
    Nephron; 2000 Apr; 84(4):305-11. PubMed ID: 10754406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term erythropoietin therapy does not increase plasma tissue factor and its inhibitor levels in hemodialysis patients.
    Borawski J; Naumnik B; Myśliwiec M
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):173-4. PubMed ID: 12812390
    [No Abstract]   [Full Text] [Related]  

  • 16. Endothelial cell activation in cutaneous vasculitis.
    Jurd KM; Stephens CJ; Black MM; Hunt BJ
    Clin Exp Dermatol; 1996 Jan; 21(1):28-32. PubMed ID: 8689765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In patients with deep-vein thrombosis elevated levels of factor VIII correlate only with von Willebrand factor but not other endothelial cell-derived coagulation and fibrinolysis proteins.
    Bombeli T; Jutzi M; De Conno E; Seifert B; Fehr J
    Blood Coagul Fibrinolysis; 2002 Oct; 13(7):577-81. PubMed ID: 12439142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin.
    London GM; Zins B; Pannier B; Naret C; Berthelot JM; Jacquot C; Safar M; Drueke TB
    Kidney Int; 1989 Nov; 36(5):878-82. PubMed ID: 2615194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human erythropoietin treatment of anemia in renal transplant patients.
    Lezaic V; Djukanovic L; Pavlovic-Kentera V
    Ren Fail; 1995 Nov; 17(6):705-14. PubMed ID: 8771243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Does long-term erythropoietin therapy influence the prevalence of serum markers of hepatitis B and C in haemodialysed uraemic patients?].
    Mesjasz J; Wiecek A; Gonciarz Z; Mazur W; Kokot F
    Pol Merkur Lekarski; 2004 Apr; 16(94):362-7. PubMed ID: 15517934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.